Announcement

Collapse
No announcement yet.

InVivo Therapeutics and Cord Blood America Receive Boost in Support as Geron Changes

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    InVivo Therapeutics and Cord Blood America Receive Boost in Support as Geron Changes

    remember, nobody is irreplaceable. That's a good thing.





    InVivo Therapeutics and Cord Blood America Receive Boost in Support as Geron Changes Strategy
    The Bedford Report Provides Equity Research on InVivo Therapeutics & Cord Blood America

    Press Release: The Bedford Report – 3 hours ago



    NEW YORK, NY--(Marketwire -11/21/11)- The stem cell industry lost one of its key players earlier this month when industry pioneer Geron Corporation announced its intention to exit the stem cell research market. The company, which was a leader in stem cell research, intends to focus on its oncology programs instead. Geron's exit has left not only the stem cell industry more wide open, but also the spinal cord injury treatment sector. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides investmhttp://finance.yahoo.com/news/invivo-therapeutics-cord-blood-america-131600442.htmlent research on InVivo Therapeutics Corporation (OTC.BB: NVIV.OB - News) and Cord Blood America Inc. (OTC.BB: CBAI.OB - News). Access to the full company reports can be found at:

    more...

    http://finance.yahoo.com/news/invivo...131600442.html

    #2
    Originally posted by manouli View Post
    remember, nobody is irreplaceable. That's a good thing.





    InVivo Therapeutics and Cord Blood America Receive Boost in Support as Geron Changes Strategy
    The Bedford Report Provides Equity Research on InVivo Therapeutics & Cord Blood America

    Press Release: The Bedford Report – 3 hours ago



    NEW YORK, NY--(Marketwire -11/21/11)- The stem cell industry lost one of its key players earlier this month when industry pioneer Geron Corporation announced its intention to exit the stem cell research market. The company, which was a leader in stem cell research, intends to focus on its oncology programs instead. Geron's exit has left not only the stem cell industry more wide open, but also the spinal cord injury treatment sector. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides investmhttp://finance.yahoo.com/news/invivo-therapeutics-cord-blood-america-131600442.htmlent research on InVivo Therapeutics Corporation (OTC.BB: NVIV.OB - News) and Cord Blood America Inc. (OTC.BB: CBAI.OB - News). Access to the full company reports can be found at:

    more...

    http://finance.yahoo.com/news/invivo...131600442.html
    Good news. I don't follow Geron's reasoning. Are they specifically a cancer research organisation? Rather worrying as stem cells seem to offer so much medical potential.

    My feeling is let Geron get on with it, and we'll wait on how much they do for oncology.
    2010 SCINet Clinical Trial Support Squad Member
    Please join me and donate a dollar a day at http://justadollarplease.org and copy and paste this message to the bottom of your signature.

    Comment

    Working...
    X